Kobayashi H, Satake N, Kaneko Y
The Third Clinical Department, Saitama Cancer Center Hospital, Ina, Japan.
Leuk Lymphoma. 1997 Dec;28(1-2):43-50. doi: 10.3109/10428199709058329.
The t(12;21) (p13;q22) is observed in approximately 20-25% of childhood B-lineage acute lymphoblastic leukemia (ALL) cases in both Asian and Caucasian populations. This translocation results in the fusion of TEL, a recently described ETS-like gene on 12p13, and AML1, which was shown to be involved in the formation of fusion genes with ETO and EVI1 in myeloid leukemias. Fluorescence in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis are useful in detecting this translocation which is not readily identified with routine cytogenetic techniques. The t(12;21) is associated with a distinct subgroup of patients characterized by an age between 1 and 10 years, an early B immunophenotype, and a good prognosis. A high incidence of the deletion of non-translocated TEL is another characteristic of leukemic cells with this translocation. TEL-AML1 hybrid protein thought to be critical in leukemogenesis possesses the HLH domain of TEL fused to almost the entire AML1 protein, although the detailed mechanisms of leukemogenesis remain obscure. RT-PCR combined with FISH analysis of posttreatment samples appears to be useful in detecting early relapse or minimal residual disease and thus, is expected to optimize the treatment strategy for patients with t(12;21).
在亚洲和高加索人群中,约20%-25%的儿童B系急性淋巴细胞白血病(ALL)病例可观察到t(12;21)(p13;q22)。这种易位导致12p13上一个最近描述的类ETS基因TEL与AML1融合,AML1已被证明在髓系白血病中与ETO和EVI1形成融合基因有关。荧光原位杂交(FISH)和逆转录聚合酶链反应(RT-PCR)分析有助于检测这种易位,而常规细胞遗传学技术不易识别。t(12;21)与一个特定的患者亚组相关,其特征为年龄在1至10岁之间、早期B免疫表型且预后良好。非易位TEL缺失的高发生率是具有这种易位的白血病细胞的另一个特征。TEL-AML1融合蛋白被认为在白血病发生中起关键作用,它具有TEL的HLH结构域与几乎整个AML1蛋白融合,尽管白血病发生的详细机制仍不清楚。RT-PCR结合治疗后样本的FISH分析似乎有助于检测早期复发或微小残留病,因此有望优化t(12;21)患者的治疗策略。